Change in Paxlovid and Molnupiravir Allocation Process
DSHS now allocates Paxlovid and/or molnupiravir based on emailed requests instead of doing case-based allocations and automatic ordering/shipping.
To obtain additional Paxlovid and/or molnupiravir for your facility, please email therapeutics@dshs.texas.gov with the number of courses requested of the specified product.
- Please include the full name of the facility and HPOP State PIN (e.g., TXA123456)
- Request quantities in multiples of 20 for Paxlovid and 24 for molnupiravir.
- Inventory reporting in HPOP must be current.
-
These are requests. Oral antivirals are subject to allocation and the request may not be filled in full.
-
Please email requests by 5:00PM on Thursday to be included in the following week’s allocation
Evusheld Request Process
Providers enrolled to provide Evusheld may request this product by emailing therapeutics@dshs.texas.gov with the number of cartons they would like to request. Requests must be in multiples of 24 cartons (1 carton = 150 mg tixagevimab plus 150 mg cilgavimab).
Evusheld Reporting Updates
Please report inventory and administration of Evusheld in HPOP by cartons (150 mg tixagevimab/150 mg cilgavimab).
The patient receiving the larger initial dose (300 mg each of tixagevimab/cilgavimab) would be reported as two units (cartons or courses) administered while the repeated. The patient receiving the smaller dose (150 mg tixagevimab/150 mg cilgavimab) would be reported as one unit administered.
For more information on HPOP reporting, visit the HPOP FAQ for COVID-19 Therapeutics Providers or contact therapeutics@dshs.texas.gov.
Bamlanivimab Expiration
Certain courses of bamlanivimab are due to expire soon. This includes lots that previously had their expiration dates extended. Providers can first confirm the expiration date of bam with the manufacturer. Then, providers can waste the expired product at their provider sites. The product does not need to be returned to the manufacturer since there is no refund for government-purchased therapeutics, and wasting on site reduces shipping costs.
Providers with questions about BAM/ETE can contact the manufacturer, Lilly, at 1-855-545-5921. Providers with questions about REGEN-COV can contact Regeneron at 844-734-6643.
There is currently no platform for providers to report waste for BAM/ETE, REGEN-COV, or Sotrovimab.
Reminder: Enter HPOP State PIN in Therapeutics Order Request Form
When requesting COVID-19 monoclonal antibodies in the Vaccine Allocation & Ordering System (VAOS), providers who have an HPOP State PIN should enter the numbers from it in the Amerisource Bergen Account Number field.
For example, if your HPOP State PIN is TXA123456, enter 123456. Providers who do not have an HPOP account should contact therapeutics@dshs.texas.gov to enroll.
Reminder: Sotrovimab EUA Changes: Decreased Time for Administration and Updated Efficacy Data
The Emergency Use Authorization (EUA) for COVID-19 therapeutic sotrovimab has been updated to include the most recent data on its efficacy against various variants.
Moreover, there has been a decrease in the time for administration from the onset of symptoms. Providers now must administer sotrovimab within seven (7) days from the onset of symptoms, instead of ten (10) days.
Please review the sotrovimab EUA Fact Sheet for more details.
Expert Tip: US HHS COVID-Therapeutics Locator
The US HHS COVID-19 Therapeutics locator now shows locations with available Sotrovimab and Bebtelovimab, in addition to Paxlovid, Molnupiravir, and Evusheld. The address and therapeutics available at each location can be accessed through the resource linked here.
|
